Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC.SI · Entity 5607 | Director | October 05, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SHOULDER INNOVATIONS, INC.
Report date October 05, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,438 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 669 · Balance 7,438 F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inari Medical, Inc.
Report date February 19, 2025 · Filed February 20, 2025
Section 16 reporting ended · disclosed 2025-02-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Child 1 | 0 |
Reported balance
After 2025-02-19 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-02-19 · Other · Disposed 1,550 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | IndirectBy Child 2 | 0 |
Reported balance
After 2025-02-19 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-02-19 · Other · Disposed 1,550 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | IndirectBy Child 3 | 0 |
Reported balance
After 2025-02-19 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-02-19 · Other · Disposed 1,550 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2025-02-19 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2025-02-19 · Other · Disposed 1,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-19 transaction · row 6
2 source rows · reconciled sequenceRow 5 · 2025-02-19 · Grant · Acquired 20,393 · Balance 717,637 F2: Pursuant to the Merger Agreement, at the Effective Time, these performance-based restricted stock units vested based on deemed achievement of maximum performance. Row 6 · 2025-02-19 · Other · Disposed 717,637 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F3: Includes 149,010 shares of restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.00 | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-02-19 · Disposition to issuer · Disposed 36,085 · Balance 0 F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.44 | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-02-19 · Disposition to issuer · Disposed 44,693 · Balance 0 F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.
F2: Pursuant to the Merger Agreement, at the Effective Time, these performance-based restricted stock units vested based on deemed achievement of maximum performance.
F3: Includes 149,010 shares of restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 02, 2022 Filed May 4, 2022 20:33 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,163 | $80.80 | $93,970.40 |
DisclosureSEC source: 0001562180-22-003739 · primarydocument.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,084 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $80.43 to $81.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 02, 2022 Filed May 4, 2022 20:33 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,119 | $79.80 | $169,096.20 |
DisclosureSEC source: 0001562180-22-003739 · primarydocument.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,247 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $79.36 to $80.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 02, 2022 Filed May 4, 2022 20:33 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,418 | $78.76 | $111,681.68 |
DisclosureSEC source: 0001562180-22-003739 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,566 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $78.36 to $79.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 02, 2022 Filed May 4, 2022 20:33 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 200 | $77.14 | $15,428.00 |
DisclosureSEC source: 0001562180-22-003739 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,366 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.11 to $77.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,606 | $92.10 | $147,912.60 |
DisclosureSEC source: 0001562180-22-003258 · primarydocument.xml · nonDerivative · entry 7 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,984 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F8 · price: This transaction was executed in multiple trades at prices ranging from $92.00 to $92.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,394 | $91.63 | $310,992.22 |
DisclosureSEC source: 0001562180-22-003258 · primarydocument.xml · nonDerivative · entry 6 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,590 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F7 · price: This transaction was executed in multiple trades at prices ranging from $90.99 to $91.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,373 | $91.86 | $126,123.78 |
DisclosureSEC source: 0001562180-22-003258 · primarydocument.xml · nonDerivative · entry 5 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,984 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F6 · price: This transaction was executed in multiple trades at prices ranging from $91.31 to $92.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,020 | $90.73 | $92,544.60 |
DisclosureSEC source: 0001562180-22-003258 · primarydocument.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,357 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $90.30 to $91.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,607 | $89.76 | $234,004.32 |
DisclosureSEC source: 0001562180-22-003258 · primarydocument.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,377 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $89.23 to $90.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 646 | $90.92 | $58,734.32 |
DisclosureSEC source: 0001562180-22-003258 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,984 F2 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 347 | $90.92 | $31,549.24 |
DisclosureSEC source: 0001562180-22-003258 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,630 F1 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 21:08 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001562180-22-002815 · primarydocument.xml · derivative · entry 6 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,100 Underlying: Common Stock · 10,000 shares Expires 2028-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Option vested with respect to 25% of the underline shares on May 3, 2019 and vest with respect to the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 21:08 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 10,000 | $0.43 | $4,284.00 |
DisclosureSEC source: 0001562180-22-002815 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:24 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 5,000 | $90.00 | $450,000.00 |
DisclosureSEC source: 0001562180-22-002138 · primarydocument.xml · nonDerivative · entry 10 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,977 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:24 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,833 | $90.25 | $165,428.25 |
DisclosureSEC source: 0001562180-22-002138 · primarydocument.xml · nonDerivative · entry 9 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,977 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F10 · price: This transaction was executed in multiple trades at prices ranging from $90.00 to $90.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:24 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,863 | $90.29 | $168,210.27 |
DisclosureSEC source: 0001562180-22-002138 · primarydocument.xml · nonDerivative · entry 8 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,810 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F9 · price: This transaction was executed in multiple trades at prices ranging from $90.00 to $90.89. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:24 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 362 | $93.05 | $33,684.10 |
DisclosureSEC source: 0001562180-22-002138 · primarydocument.xml · nonDerivative · entry 7 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,673 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F8 · price: This transaction was executed in multiple trades at prices ranging from $92.88 to $93.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:24 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,852 | $92.22 | $170,791.44 |
DisclosureSEC source: 0001562180-22-002138 · primarydocument.xml · nonDerivative · entry 6 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,035 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F7 · price: This transaction was executed in multiple trades at prices ranging from $91.73 to $92.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:24 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 747 | $91.01 | $67,984.47 |
DisclosureSEC source: 0001562180-22-002138 · primarydocument.xml · nonDerivative · entry 5 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,887 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F6 · price: This transaction was executed in multiple trades at prices ranging from $90.63 to $91.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:24 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,776 | $90.02 | $159,875.52 |
DisclosureSEC source: 0001562180-22-002138 · primarydocument.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,634 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $89.50 to $90.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:24 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 263 | $89.08 | $23,428.04 |
DisclosureSEC source: 0001562180-22-002138 · primarydocument.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,410 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $88.49.60 to $89.48 The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:24 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,167 | $90.06 | $285,220.02 |
DisclosureSEC source: 0001562180-22-002138 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,673 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $90.00 to $90.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:24 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,137 | $90.04 | $282,455.48 |
DisclosureSEC source: 0001562180-22-002138 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,840 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $90.00 to $90.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 17, 2022 Filed Feb 23, 2022 00:17 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 29,879 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001711 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,977 F1 · shares: 2022 Annual Restricted Stock Units grant ("RSUs"). Vesting Commencement Date begins January 1, 2022, 1/16th of the RSUs shall vest on each quarterly anniversary of the vesting Commencement Date. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:41 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 409 | $75.41 | $30,841.30 |
DisclosureSEC source: 0001562180-22-001043 · primarydocument.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,098 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $75.33 to $75.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · balance_after: Includes 119 shares acquired under the Employee Stock Ownership Plan on January 31, 2022. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:41 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,310 | $74.59 | $97,716.70 |
DisclosureSEC source: 0001562180-22-001043 · primarydocument.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,388 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $74.23 to $74.97. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:41 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,381 | $73.63 | $101,676.68 |
DisclosureSEC source: 0001562180-22-001043 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,698 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $73.09 to $74.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:41 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,900 | $72.70 | $138,124.30 |
DisclosureSEC source: 0001562180-22-001043 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,079 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $72.05 to $72.97. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 01:50 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 400 | $78.29 | $31,316.32 |
DisclosureSEC source: 0001562180-22-000562 · primarydocument.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,979 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $78.15 to $78.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · balance_after: This amount reflects an updated holding to correct a typographical error in the total on a prior report. It also includes 695 shares acquired under the Employee Stock Ownership Plan in 2021. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 01:50 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,400 | $77.31 | $108,236.66 |
DisclosureSEC source: 0001562180-22-000562 · primarydocument.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,379 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $77.05 to $77.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 01:50 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,976 | $76.58 | $151,325.64 |
DisclosureSEC source: 0001562180-22-000562 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,779 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $76.05 to $77.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 01:50 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,224 | $75.46 | $92,365.49 |
DisclosureSEC source: 0001562180-22-000562 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,755 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $74.98 to $75.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 22:19 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 411 | $91.27 | $37,511.97 |
DisclosureSEC source: 0001562180-22-000121 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,194 F1 · shares: Shares surrendered for tax purposes upon the vesting of 2021 annual Restricted Shares Units Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:55 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 22,222 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-21-007758 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,605 F1 · kind: The reporting person contributed the shares to a private exchange fund in exchange for an interest in the private exchange fund. F1 · price: The reporting person contributed the shares to a private exchange fund in exchange for an interest in the private exchange fund. Read SEC document |
| October 19, 2021 Filed Oct 21, 2021 00:29 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 500 | $89.16 | $44,582.00 |
DisclosureSEC source: 0001562180-21-006593 · primarydocument.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,827 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $88.89 to $89.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 19, 2021 Filed Oct 21, 2021 00:29 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 5,508 | $88.40 | $486,924.83 |
DisclosureSEC source: 0001562180-21-006593 · primarydocument.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,327 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $87.89 to $88.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 19, 2021 Filed Oct 21, 2021 00:29 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,812 | $86.93 | $157,519.33 |
DisclosureSEC source: 0001562180-21-006593 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,835 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $86.61 to $87.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 19, 2021 Filed Oct 21, 2021 00:29 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,180 | $85.47 | $100,851.65 |
DisclosureSEC source: 0001562180-21-006593 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,647 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $85.07 to $85.78. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 22:28 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 347 | $78.70 | $27,308.90 |
DisclosureSEC source: 0001562180-21-006274 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,827 F1 · shares: Shares surrendered for tax purposes upon the vesting of 2021 annual Restricted Shares Units Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 23:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,801 | $81.11 | $146,072.09 |
DisclosureSEC source: 0001562180-21-006012 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,174 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $81.00 to $81.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 23:57 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 7,199 | $80.66 | $580,669.90 |
DisclosureSEC source: 0001562180-21-006012 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,975 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $79.99 to $80.97. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 19, 2021 Filed Aug 19, 2021 23:43 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,100 | $73.06 | $153,428.94 |
DisclosureSEC source: 0001562180-21-005466 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,174 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $72.92 to $73.19. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 19, 2021 Filed Aug 19, 2021 23:43 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 6,900 | $72.53 | $500,486.67 |
DisclosureSEC source: 0001562180-21-005466 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,274 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.92 to $72.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 22:25 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Option · Derivative | 20,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001562180-21-005502 · primarydocument.xml · derivative · entry 6 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,434 Underlying: Common Stock · 20,000 shares Expires 2028-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is vested and exercisable as to 201,100 shares, and the remaining shares will vest and become exercisable in equal monthly installments until May 3, 2022. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 22:25 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 20,000 | $0.43 | $8,568.00 |
DisclosureSEC source: 0001562180-21-005502 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 23:21 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 200 | $86.87 | $17,374.00 |
DisclosureSEC source: 0001562180-21-005024 · primarydocument.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,174 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $86.87 to $86.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 23:21 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 4,059 | $85.79 | $348,241.09 |
DisclosureSEC source: 0001562180-21-005024 · primarydocument.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,374 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $85.46 to $86.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 23:21 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,541 | $85.05 | $301,155.68 |
DisclosureSEC source: 0001562180-21-005024 · primarydocument.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,433 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $84.42 to $85.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 23:21 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,200 | $83.42 | $100,100.04 |
DisclosureSEC source: 0001562180-21-005024 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,974 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $83.12 to $83.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 00:34 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 347 | $95.99 | $33,308.53 |
DisclosureSEC source: 0001562180-21-004838 · primarydocument.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,174 F1 · shares: Shares surrendered for tax purposes upon the vesting of 2021 annual Restricted Shares Units Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.